Search
Elotuzumab
go.drugbank.com/drugs/DB06317ApprovedInvestigationalElotuzumab is produced in NS0 cells by recombinant DNA technology. Elotuzumab has a theoretical mass of 148.1 kDa for the intact antibody. Elotuzumab was approved on November 30, 2015 by the U.S. … Elotuzumab targets SLAMF7, also known as Signaling Lymphocytic Activation Molecule Family member 7, a cell surface glycoprotein.
Enoxaparin
go.drugbank.com/drugs/DB01225ApprovedInvestigationalInitially approved by the FDA in 1993, it is administered by a subcutaneous or intravenous injection and marketed by several pharmaceutical companies. … Enoxaparin is a common low-molecular-weight heparin (LMWH) used in the prevention and management of various thromboembolic disorders.
Products: ENOX 10000 ANTI-XA IU/1ML KULLANIMA HAZIR ENJEKTOR, 2 ADET, ENOX 10000 ANTI-XA IU/1ML KULLANIMA HAZIR ENJEKTOR, 20 ADETBicalutamide
go.drugbank.com/drugs/DB01128ApprovedInvestigationalIt is comprised of a racemic mixture that is a 50:50 composition of the (R)-bicalutamide and (S)-bicalutamide enantionmers. Bicalutamide binds to the androgen receptor.
Categories: Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic IndexProducts: BICALUTAMID 1A PHARMA50MG, BICALUTAMID 1A PHARMA 50Mipomersen
go.drugbank.com/drugs/DB05528ApprovedIt is marketed under the brand name Kynamro in the United States, and the FDA label includes a black box warning of hepatoxicity. … Mipomersen sodium, which was known as the investigational drug, isis-301012, is the salt form of a synthetic phosphorothioate oligonucleotide.
Categories: DNA, Antisense, Compounds used in a research, industrial, or household settingCefdinir
go.drugbank.com/drugs/DB00535ApprovedInvestigationalCefdinir was approved by the FDA in 1997 to treat a variety of mild to moderate infections and was initially marketed by Abbvie. … Cefdinir, also known as Omnicef, is a semi-synthetic, broad-spectrum antibiotic belonging to the third generation of the cephalosporin class.
ZYC300
go.drugbank.com/drugs/DB04986InvestigationalZYC300 is a plasmid DNA of CYP1B1 encapsulated in biodegradable poly-DL-lactide-coglycolide microparticles. … It is designed as a vaccine, intended to increase immune system sensitivity to CYP1B1, an enzyme highly prevalent in tumor cells.
Busulfan
go.drugbank.com/drugs/DB01008ApprovedInvestigationalBusulfan is a bifunctional alkylating agent, having a selective immunosuppressive effect on bone marrow. It is not a structural analog of the nitrogen mustards. … According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), busulfan is listed as a known carcinogen.
Categories: Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic IndexBacillus calmette-guerin substrain russian BCG-I live antigen
go.drugbank.com/drugs/DB16648ApprovedInvestigationalthought to work by stimulating a local immune and inflammatory response in the bladder. … [L32729,A232264] The live Russian BCG-I substrain of BCG was granted a notice of compliance with conditions by Health Canada in February 2021.
Voretigene neparvovec
go.drugbank.com/drugs/DB13932ApprovedInvestigational[L1094] An adeno-associated virus is a small virus that infects humans and other primates. It is not pathogenic and it causes a very mild immune response. … [A31478] VN-rzyl was developed by Spark Therapeutics Inc. and FDA approved on December 19, 2017.[L1095]
WP-1122
go.drugbank.com/drugs/DB17192InvestigationalWP-1122 is a prodrug of 2-deoxy-D-glucose (2-DG). It was granted FDA orphan designation for the treatment of glioblastoma multiforme.[L47361]
Synonyms: 3,6-di-O-acetyl-2-deoxy-D-glucopyranose, an acetic acid diester of 2-deoxy-D-glucose